AcquisitionsApr 9, 2026, 08:16 AM
Assertio Holdings to be Acquired by Garda Therapeutics for $18.00 Per Share Plus CVR
AI Summary
Assertio Holdings, Inc. has entered into a definitive merger agreement to be acquired by Garda Therapeutics, Inc. through a cash tender offer. Shareholders will receive $18.00 per share in cash, along with one contingent value right (CVR) per share, representing potential additional cash payments. Assertio's Board of Directors has unanimously approved the transaction and recommended that stockholders tender their shares, signaling strong confidence in the deal's value. This acquisition will result in Assertio becoming a wholly-owned subsidiary of Garda Therapeutics, marking a significant strategic shift for the company.
Key Highlights
- Assertio Holdings, Inc. (ASRT) will be acquired by Garda Therapeutics, Inc. through a cash tender offer.
- Shareholders will receive a Base Purchase Price of $18.00 per share in cash.
- In addition to the cash, shareholders will receive one Contingent Value Right (CVR) per share, representing the right to potential future cash payments.
- The Company’s Board of Directors has unanimously approved the Merger Agreement and recommended that stockholders accept the Offer and tender their shares.
- Purchaser is required to commence the Offer within ten (10) business days following the execution of the Merger Agreement.
- The Offer will initially expire at one minute after 11:59 p.m., Eastern Time, on the date that is twenty (20) business days following its commencement.